In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
AUTOR(ES)
Biavasco, F
RESUMO
Seventy strains of Clostridium difficile, all isolated from symptomatic patients, were found to be uniformly susceptible to ramoplanin, a new glycolipodepsipeptide antibiotic, and to four glycopeptides (vancomycin, teicoplanin, and two semisynthetic teicoplanin derivatives). Ramoplanin is recommended for further evaluation in the treatment of C. difficile-associated disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=244968Documentos Relacionados
- Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
- In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
- Effect of L-cysteine on the activity of penicillin antibiotics against Clostridium difficile.
- In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.
- In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile.
